Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. In vitro 4-1BB stimulation promotes expansion of CD8+ tumor-infiltrating lymphocytes from various sarcoma subtypes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Evaluation of complement proteins as screening markers for colorectal cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Mulig sammenhæng mellem marginal parodontitis og iskæmisk hjertesygdom

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Rikke Baek Sørensen
  • Sine Reker Hadrup
  • Tania Køllgaard
  • Inge Marie Svane
  • Per thor Straten
  • Mads Hald Andersen
Vis graf over relationer

Based on the detection of spontaneous immune responses in cancer patients with cancer of different origin, Bcl-X(L) was recently described as a highly interesting tumor antigen recognized by CD8 positive cytotoxic T lymphocytes. To further characterize Bcl-X(L) as a tumor antigen we isolated and expanded Bcl-X(L) specific T cells from the peripheral blood of a breast cancer patient hosting a strong Bcl-X(L) specific T cell response. We describe that HLA-A2 restricted Bcl-X(L) specific T cell clones very efficiently lyse peptide pulsed T2 cells. Furthermore, tumor cell lines of different origin, i.e., breast cancer, colon cancer, and melanoma, are efficiently lysed in an HLA-dependent manner. Finally, ex vivo-isolated leukemia cells, but not non-malignant B and T cells are killed by Bcl-X(L) specific T cells. Our data underline Bcl-X(L) as an universal tumor antigen widely applicable in specific anticancer immunotherapy.

OriginalsprogEngelsk
TidsskriftCancer immunology, immunotherapy
Vol/bind56
Udgave nummer4
Sider (fra-til)527-33
Antal sider7
ISSN0340-7004
DOI
StatusUdgivet - apr. 2007

ID: 61783880